Results 171 to 180 of about 4,673,170 (295)
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
Building Public Health Quantitative Methods Capacity and Networks in sub-Saharan Africa: An Evaluation of a Faculty Training Program. [PDF]
Ntshebe O+7 more
europepmc +1 more source
The Engines of the Human Body: Being the Substance of Christmas Lectures Given at the Royal Institution of Great Britain, Christmas, 1916–1917 [PDF]
C. L. E.
openalex +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop+10 more
wiley +1 more source
Pediatric Radiation Oncology in the Era of COVID-19: A Single Institution Analysis. [PDF]
Pasli M+7 more
europepmc +1 more source
Evolution of Law: Select Readings on the Origin and Development of Legal Institutions
Wendy Parker+2 more
openalex +2 more sources
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source
Impact of Preoperative Conjunctival Vascular Area on Surgical Outcomes in Trabeculectomy with Mitomycin C for Glaucoma: A Comprehensive Analysis. [PDF]
Hayakawa Y, Inada T.
europepmc +1 more source